Type IlAvon Willebrand disease (vWD) is an autosomal dominant bleeding disorder characterized by a qualitative defect in von Willebrand factor (vWF). A number of missense mutations responsible for type IIA vWD have recently been identified. This report examines the type IIA vWD mutations Leu777 + Pro and lle865 + Thr by expression of recombinant vWF containing mutant and wild-type ( w r ) sequences. Recombinant vWF containing the L777P mutation (vWFL777P) showed markedly impaired secretion compared with that for wild-type vWF (vWFWT) after DNA transfection into mammalian cells. Multimer analysis of secreted vWFL777P showed predominantly low molecular weight forms. In contrast, recombinant vWF containing the 1865T mutation (vWF1865T) was processed in a
ON WILLEBRAND FACTOR (vWF) is a multimeric plasma glycoprotein that plays several important roles in hemostasis.' vWF binds platelets to the subendothelium at sites of vascular injury. In addition, vWF cames and stabilizes factor VI11 in the circulation. The vWF gene, located on chromosome 12, spans 178 kb and is interrupted by 51 vWF is synthesized from an 8.7-kb mRNA and is expressed exclusively in endothelial cells and megakaryocytes.
Synthesis of vWF is a complex, multistep process that results in assembly of multimers of up to 100 sub unit^.^ Studies in endothelial cells indicate that dimerization by disulfide bonding at the carboxyl-termini occurs in the endoplasmic reticulum (ER), whereas further multimerization takes place in Golgi or post-Golgi compartments through disulfide linkages at the amino-termini. In the blood vessel, vWF is constitutively secreted by endothelial cells. The relative contributions of different endothelial cell populations to plasma vWF is unknown. vWF is also stored within intracellular granules in both endothelial cells (Weibel-Palade bodies) and platelets (a-granules). These specialized granules release vWF in response to a variety of stimuli including vascular damage. The vWF stored within these granules contains larger multimers than those that are constitutively secreted by endothelial cells. These high molecular weight (HMW) species appear to be most effective in platelet bindir~g~.~; therefore, rapid release of stored vWF into the circulation may be particularly useful at times of vessel injury.
Defects in vWF result in von Willebrand disease (vWD), the most common inherited bleeding disorder in humans. Several population studies suggest that this disease may affect as much as 1% of the population. vWD is a phenotyp ically heterogeneous disorder with over 20 distinct subtypes identified. However, these subtypes can be divided into two major categories, depending on whether there are quantitative (type I and type 111) or qualitative (type 11) defects in vWF.','
Type IIA vWD, the most common qualitative form ofthe disease, is characterized by a relative decrease in circulating intermediate and HMW vWF multimers and is inherited in an autosomal dominant pattern. An additional distinguish-V B/ood,Vol83,No6 (March15),1994:pp1551-1557 pattern similar to vWFWT, with secretion of the full spectrum of vWF multimers. Thus, L777P and 1865T are subclassified as type IIA group I and group II mutations. respectively. Analysis of platelet vWF from a patient heterozygous for the L777P mutation shows reduced large vWF multimers in a pattern similar to plasma, consistent with the intracellular transport defect predicted for a group I mutation. An increase in the proportion of high molecular weight multimers observed in type IIA vWD patient plasma, after renal transplantation from a normal donor, suggests that the kidney endothelium may be a major source of plasma vWF. ing characteristic of this subtype is the relative increase in a 176-kD vWF carboxy-terminal proteolytic fragment.99'0 Distinct phenotypic differences are seen among patients with type IIA VWD."*~' Weiss et all' recognized that platelets from some type IIA patients contain diminished intermediate and HMW multimers similar to the pattern seen in type IIA plasma, whereas platelets from other type IIA patients contain the full spectrum of vWF multimers. Others have noted that loss ofplasma HMW multirners in some, but not all type IIA patients, can be prevented by collection of blood in the presence of protease inhibit~rs.",'~ These data suggest that extracellular proteolysis may result in the loss of HMW multimers in a subset of type IIA vWD patients.
A number of missense mutations responsible for type IIA vWD have been identified.14 Most of these mutations are clustered within the A2 homologous repeat near the proteolytic cleavage site that generates a 176-kD proteolytic fragment associated with type IIA vWD plasma." Expression of recombinant vWF containing these mutations by DNA transfection into mammalian cells has elucidated two distinct pathogenic mechanisms for type IIA vWD: impaired intracellular transport of HMW multimers (group I mutations) and increased sensitivity to proteolysis resulting in degradation to lower molecular weight vWF forms in plasma (group I1 mutation^).'^,'^ In this report, we characterize the biosynthesis of vWF containing each of 2 previously reported type IIA vWD mutations, Leu777 + Pro (L777P) and Ile865 -+ Thr (I865T),I7 leading to their subclassification as group I and group 11, respectively. In addition, analysis of plasma vWF from a Type IIA vWD patient with the L777P mutation after kidney transplantation suggests that renal endothelial cells are a major site of plasma vWF synthesis.
MATERIALS AND METHODS
Patient material. Patients A7 and A 12 were diagnosed with type IIA vWD based on decreased plasma vWF antigen, decreased ristocetin cofactor activity (disproportionately decreased compared with vWF antigen level), and an abnormal vWF multimer pattern. Patient A7 was originally reported as part of a large pedigree with "variant von Willebrand disease" by Green and Philip (corresponding to individual IV-46 in the original pedigree'*). Later, clinical analysis of plasma vWF multimers from patient A7 (Blood Center of Southeastern Wisconsin, Milwaukee, WI) showed loss of HMW but not of intermediate-sized vWF multimers (see Fig 4A) . This pattern was interpreted as consistent with type IIB or an acquired form of vWD. However, the clinical phenotype of this patient and the autosomal dominant inheritance pattern in this family is most consistent with type IIA vWD. None ofthe family members showed thrombocytopenia or other characteristics of type IIB vWD. Patient A7 also has type I diabetes mellitus and, as a result, developed endstage renal disease. In July 199 I , the patient received a kidney transplant from one of her sisters previously determined not to have type IlA vWD based on normal vWF antigen and ristocetin cofactor activity (corresponding to patient IV-48 in the original pedigree'*).
Since transplantation, the patient has been maintained on immunosuppressive therapy consisting of steroids, azathioprine, and cyclosporine. Her serum creatinine level has ranged from 1.4 to 1.7 mg/dL. The patient's clinical evaluation before and more than I year after transplant are shown in Table 1 .
Patient A 12 has also been previously reported as a member of a large pedigree with hereditary hemorrhagic telangectasia and type IIA vWD.I9 This patient corresponds to individual 11-6 from family A in the original report. DNA ana1y.si.s. Patient A7 was previously reported to be heterozygous for a T + C mutation at nucleotide (nt) 461917 (based on the numbering of Bonthron et al," where the A ofthe initiator ATG codon is designated + I), resulting in the substitution of proline for leucine at amino acid 777 of the mature vWF subunit. This mutation results in loss of a PSI I site. Genomic DNA from patient A7 and her mother was prepared from peripheral blood (PB) lymphocytes, as previously described.2 DNA was amplified using the polymerase chain reaction (PCR; primers A and C"). The PCR product was digested with PS/ I and electrophoresed on a 2% agarose gel. Patient A 12 was previously shown to have a T + C transition at nt 4883, resulting in a substitution ofthreonine for isoleucine at amino acid 865 (1865T).I9 Expression vecfor construction. The type IIA vWD mutations identified in patients A7 (L777P) and AI2 (I865T) were inserted into full-length vWF cDNA in the expression vector pMT2, under the control of the adenovirus major late promoter." Briefly, genomic DNA from patient A7 was amplified by PCR as previously described. 17 An NCO I-Kpn l fragment (nts 4482-4752) containing the mutation was inserted into full-length vWF cDNA in pMT2 using standard method^.'^.^' The mutation identified in patient A12 (1865T) was prepared by site-directed mutagenesis of a vWF Sac I fragment [(+)3086-(+)6676] subcloned into the phagemid pSE-LECT using a commercial kit (Promega Corp, Madison, WI). The 19-bp mutagenesis oligonucleotide, TGGTGCCCACTGGAG-TGGG (mutation is underlined), corresponds to the vWF cDNA sense strand beginning at nt 4874. A Kpn I-Xmn I fragment (nts 4752-5 134) containing the mutation was subcloned into full-length vWF cDNA as above. In both constructions, all segments derived by PCR or mutagenesis were sequenced to verify the presence of the corresponding type IIA mutations and to exclude polymerase errors. pMT2-derived plasmids containing the full-length vWF cDNA with wild-type sequence, L777P. or 1865T mutations are designated pWTvWF. pL777P. and p1865T, respectively. The @galactosidase (P-gal)-expression plasmid (pJ3@-Gal), which contains the SV40 origin and LacZ cDNA under the direction of an SV40 enhancer/promoter. was kindly provided by L. Spain (Whitehead Institute, Cambridge. MA).
Cc.// c~r/rzrre and trun.s/izc/ion. COS-7 cells were maintained in Dulbecco's modified Eagle's medium (JRH Biosciences, Lenexa, KS) supplemented with 7.5% fetal bovine serum (GIBCO-BRL Life Technologies, Inc. Gaithersburg, MD). On the day of transfection, cells were split 1.7 from a near confluent plate and transfected within I to 4 hours by a modified standard calcium phosphate-mediated transfection method.23 For each transfection, 10 pg of vWF and 2 pg of P-gal expression plasmid were used. Approximately 36 hours after transfection. cells were rinsed twice with phosphatebuffered saline and transferred into 3-mL serum-free AIM-V medium (GIBCO-BRL). After 24 hours in serum-free medium, cell lysates and cell media were harvested from transfections, essentially as previously described." A mixture of protease inhibitors was added to final concentrations of 0.5 mg/mL leupeptin, 0.2 mg/mL aprotinin, 10 mg/mL bovine trypsin inhibitor, 0.7 mg/mL pepstatin, and 5 mmol/L iodoacetic acid (all purchased from Sigma Chemical Co. St Louis, MO) for both lysates and medium. Phenylmethylsulfonyl fluoride and EDTA were also added to final concentrations of 2 mmol/L and 5 mmol/L. respectively. vWF in cell lysates and cell medium was quantitated by enzyme-linked immunosorbent assay (ELISA), as previously described," using a commercial reference plasma (Bio/Data Corp, Horsham, PA) as a standard (assuming I O pg/mL vWF concentration in normal plasma). @-gal ELISA was also performed as describedt7 using a commercial @-gal standard (Sigma). Wild-type vWF and vWF containing the mutations L777P or I865T will be referred to as vWFWT, vWFL777P. and vWF1865T, respectively. ~g u r o s e g d electrophoresis. Preparation of samples from transfections and electrophoresis in vertical I .5% sodium dodecyl sulfate (SDS)-agarose multimer gels were performed, as previously described,24 using chemiluminescence (Amersham Corp. Arlington Heights, IL) for detection of vWF multimers. After obtaining informed consent, PB was collected from patients into EDTA. For plasma and platelet lysates, PB was centrifuged at 1 00g for 10 minutes to obtain platelet-rich plasma, followed by centrifugation at 2500:: to form a platclct pcllet and platelet-poor plasma. Platclctpoor plasma was stored at -80°C. Platclct lysates were prepared a s described." Washed platclct pellets derived from I mL of whole blood wcrc rcsuspendcd in 15 pL Tris-bufcrcd saline (10 mmol/L Tris-HCI, pH 7.5, and 140 mmol/l. NaCI) with 3% bovine scrum albumin. I'latclcts were lysed at 37°C with 1/40 volume of20'X: Triton X-100. The clinical multimer analysis ofpatient A7, shown in Fig 4A, wab performed in the clinical reference laboratory at the Blood Center of Southeastern Wisconsin.
RESULTS
Stcuclj)-stutc anal~..si.s of' rcwmhinant v W'F containing type IIA r. MVl> mutations L777P or 18657'. The previously identified type IIA vWD mutations, 7'4619 + C (L777P) and T4883 + C (1865T), were inserted into full-length vWF cDNA in the expression vector pMT2. To examine the synthesis ofvWF containing these mutations, ("33-7 cells were transfected with the vWF expression constructs pWTvWF. pL777P, or pI865T, and vWF in cell media and in cell lysates from transfected cells was quantitated by ELISA. Cells were cotransfcctcd with a @-gal expression vector (pJ3fi-Gal) as an internal control for transfection efticicncy. vWF-ELISA values in lysates and mcdia were normalized for transfection efficiency using intracellular @-gal levels from each transfection. Comparisons of the vWF level in conditioned mcdia bctwcen WT and each mutant showed that vWFIX65T secretion was similar to vWFWT, whereas the lcvcl ofvWFL777P was markedly reduced (Fig 1) . Intracellular levels of each mutant were greater than that of vWFWT.
The dcfectivc secretion of vWFL777P is similar to that previously observed with the group I type IIA mutations VX44D, S743L, and G742R.I' Intracellular L777P was entirely sensitive to digestion with endoglycosidase H (data not shown), indicatingthat mutant vWFwas rctaincd in the ER, which is similar to results with the other group I vWD mutations." In contrast, the relative quantity of extracellular vWFI865T in steady-state analysis was indistinguishable from that of vWFWT, which is consistcnt with classification ofthis mutation as a group I1 defect. However, thc apparent intracellular accumulation ofvWF1865T may suggest a subtle defect in transport from the ER.
MuI1inwr analysis of sccrctcd rcmnhinant vMIF.
Recombinant vWF secreted from cells transfected with pWTvWF, pL777P, and pI865T was analyzed by SDS-agarose gel electrophoresis to assess the effect of these mutations on multimer structure. The multimcr pattern of extracellular vWF1865T was indistinguishable from that of W T ( Fig  2) . However, only trace amounts of vWFL777P were seen in the conditioned medium ( Fig 2B) , and these were predominantly low molecular weight multimer species. When equal amounts (as quantitated by ELISA) of vWFL777P as compared with vWFWT and vWFI865T were analyzed, larger multimers were observed, although reduced in quantity (Fig 2A) . after kidncy transplant. Because prctransplant plasma was unavailable for dircct comparison in our laboratory, blood was obtained from patient A7's mother (corresponding to individual 111-25 in the original pedigree'&) who is also affected with a moderately scvcrc bleeding diathesis. The T4h 1 '>C mutation reported i n this family results in a loss of a P.st I restriction sitc. DNA restriction analysis with A / I, shown in Fig 3, shows that both patient A7 and her mother are heterozygous for thc T4h19C (L777P) mutation. Clinical analysis (Blood Center of Southeastern Wisconsin) of plasma vWF from patient A7 before renal transplant is shown i n Fig 4A. Although analyLed in different gel systems. plasma from the mother of patient A7 shows a type 11-vWD multimcr pattcrn similar to that of patient A7 before renal transplant, with decreased intermediate and HMW multimers when compared with that for normal controls ( Figs 4B and C) . Even on long exposure of the lane containing the mother's plasma. intermediate molecular weight multimers are greatly decreased, and HMW multimers arc absent ( Fig 4C) . By comparison, the vWF multimer pattern seen in patient A7 plasma after renal transplantation has a greater relative proportion of intermediate and HMW multimers ( Figs 4B and C) plantation shows an increase in circulating HMW vWF multimers in the presence ofthe normal renal allograft.
Multimcr analyxis of' plasma v WI,Jkorn a typcl I l A v WD

DISCUSSION
In this report. two type IIA vWD mutations, L777P and 1865T, are subclassified into groups I and 11. respectively, based on steady-state analysis of recombinant mutant vWF expressed in heterologous cells. The group I type HA mutations cause selective retention of HMW vWF in the ER. Expression of vWFL777P in COS-7 cells showed impaired transport/secretion, with more pronounced effects on the HMW vWF forms, which is consistent with the group I classification. This is similar to our previous observations for the mutations V844D. S743L. and G742R.I7 The decrease in large vWF multimers observed in patient A7's platelet lysate is consistent with a transport defect in vivo that also affects the storage of HMW vWF multimers in the a-granule.
In contrast. 1865T can be categorized as a group I1 mutation. similar to R834W and G742E,I7 based on its normal synthesis and secretion in COS-7 cells. The location of the 1865T mutation within the region ofclustered type IIA mutations, the coinheritance with type HA vWD in a large pedigree. and its absence from a panel of 134 normal allele^'^ all support the characterization of this amino acid substitution as an authentic type IIA vWD mutation. However, the occurrence of a rare. private DNA sequence polymorphism cannot be completely excluded. To date, a total of 15 type that for the patient's mother. Comparison of patient A7's plasma multimer pattern with that of a normal control shows HMW multimeric species. similar to that of normal controls: however, it is present in relatively reduced quantity. Examination of platelet vWF from patient A7 ( Fig 4D) shows a relative decrease in the large and intermediate-sized multimers compared with a normal platelet control, closely resembling the pattern observed in the plasma of patient A7's mother and in patient A7's plasma before transplant. We hypothesize that the increased HMW and intermediate vWF multimers seen in patient A7's plasma but not in her platelets result from the contribution of the normal transplanted kidney to circulating vWF. Comparison of patient A7's vWF multimer pattern before and after renal trans- HA vWD mutations have been rep~rted.'~.~'Ofthese mutations, 9 (including those in the current report) have been characterized by transfection analy~is.'~.'~.'~ with 5 mutations resulting in a normal group I1 pattern of secretion.
Several lines of evidence suggest that extracellular proteolysis of vWF multimers may result in the type IIA vWD phenotype in group I1 patients.'"'.'.'* The groups I and I1 mutations are clustered near the proteolytic cleavage site between Tyr842 and Met843.I5 Cleavage at this site generates a 176-carboxyl-terminal fragment that is markedly increased in type IIA vWD plasmacompared with that in normal plasma.u~'O~'g In addition, the full spectrum of vWF multimers has been previously observed in platelet lysates from two individuals with group I1 mutations, supporting the hypothesis that a postsecretory defect accounts for the absence of plasma HMW multimeric species in these patients." Two additional type IIA vWD mutations (E875K and S85OP). characterized via analysis of recombinant vWF, can also be classified as group I1 mutation^.^"." However, correlation with platelet vWF multimers from patients with these mutations is not available.
Group I or group I1 type IIA vWD mutations cannot be distinguished on the basis of the location or type of amino acid sub~titution.'~ Both severe group I mutations, L777P and V844D. result from nonconservative amino acid substitutions. Other group I and I1 mutations include both nonconservative substitutions, such as G742E (group 11) and G742R (group I), and conservative ones, such as 1865T (group 11) and S743L (group I). We hypothesize that all of these mutations perturb the same sensitive structure exposed on the surface of the vWF m~lecule.'~ The altered structure that results from group I mutations interferes with intracellular transport, possibly through increased affinity for a resident ER protein(s). In contrast, the altered conformation produced by group I1 mutations escapes recognition by the ER machinery but results in increased susceptibility of vWF to a plasma protease(s) after secretion into plasma.
Most subtypes of type I1 vWD are currently classified based on differences in plasma vWF multimer patterns. The large number of multimer variants observed with both lowand high-resolution gel analysis and the occurrence of inconsistencies between clinical laboratory assays and multimer analyses have made subtype assignment difficult. Patient A7 shows the potential problem of vWD classification based largely on use of vWF multimer pattern. Although the multimers were initially interpreted as most consistent with type IIB or acquired vWD, the other clinical features. the location of the identified mutation (L777P)I7 and the results of transfection analysis, taken together, are most consistent with the diagnosis ofgroup I type IIA vWD.
The distinction between group I and group I1 may have important implications for the treatment of type IIA vWD. Type IIA vWD patients have a variable response to I-deamino 8-D-arganine vasopressin (DDAVP). an analogue of For personal use only. on October 30, 2017. by guest www.bloodjournal.org From vasopressin used to treat various forms of vWD, via release of stored vWF. Some investigators have reported little effect of this drug in type IIA vWD patient^,^' whereas others document good clinical response^.^' Intracellular storage pools in group I patients would not be predicted to contain HMW vWF multimers, and, thus, DDAVP would not be expected to increase the amount of circulating HMW vWF multimers. However, because storage granules from group I1 patients should contain the full range of vWF multimers, DDAVP would be expected to result in a transient increase in plasma HMW vWF multimers and improved hemostasis. Thus, the division of type IIA vWD into group I and group I1 may have significant implications for therapy; however, this hypothesis remains to be tested.
Of note, patient A7 had an improvement in her vWF antigen level and bleeding symptoms (menorrhagia and bruising) after transplantation of a normal kidney from her unaffected sister. In patients without vWD, previous investigators have reported that vWF antigen levels increase after placement of a renal allograft, but levels appear to return to baseline approximately 4 to 6 months after t r a n~p l a n t .~~ Others report that this increase in vWF may be partially caused by cyclosporine nephrotoxicity, although this is contr~versial.~~-'~ In addition to an increase in vWF antigen (persisting for > 16 months after transplant), patient A7 also appears to have a greater percentage of circulating HMW vWF multimers (Fig 4) . We hypothesize that the quantitative and qualitative changes in plasma vWF observed in this patient may be caused by the contribution of the transplanted kidney to circulating vWF. Webster et previously reported no improvement in factor VI11 levels or bleeding times in two pigs with severe vWD, who received normal porcine kidney allografts; however, these two animals lived for 6 and 7 days. During this time, the animals apparently suffered from continual hemorrhage that eventually led to their deaths. Similarly, Mannucci et described a type 111 vWD patient who underwent a liver transplant for management of chronic hepatitis and hepatocellular carcinoma. Three months after transplantation, the patient's vWF antigen was approximately twenty times higher than before transplantation, although still remarkably low (1.02%; with normal range, 50% to 150%). However, no clinical information was provided to document the status of the transplanted organ or the drug regimen used for immun~suppression.~~ It has been previously shown that endothelial cells remain of donor origin in transplanted organs," except in the setting of organ rejection and cyclosporine t o~i c i t y .~~,~' In patient A7, we have documented both a quantitative as well as a qualitative improvement in circulating vWF after successful placement of a normal renal allograft, which was also associated with a subjective improvement in bleeding symptomatology. These observations suggest that, with continued improvement in organ transplantation and endothelial cell graft procedures, such approaches may eventually have a role in the management of severe forms of vWD.
